Scrip
US FDA accepts Somaxon's complete response for Silenor
27 January 2010
Katie McQue
Please Login to read the full article.
27 January 2010
Katie McQue
The US FDA has accepted Somaxon's resubmission of the NDA for its troubled insomnia drug Silenor (doxepin) following the complete response letter it issued in June. The company's share price soared by 82%, closing at $2.40 on Nasdaq on January 22nd.
The resubmission has been designated as...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA needs more on Somaxon's insomnia drug Silenor
- US panel backs Acorda's fampridine for MS, but urges study of lower dose
- Complete response letter for GSK/XenoPort's Horizant over cancer concern
- Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
FEATURES
- Spanish generics industry fights for its future
- Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
